Rivus Pharmaceuticals
Rivus Pharmaceuticals is a privately held clinical-stage biopharmaceutical company founded in 2019, with corporate offices in South San Francisco, California and research operations in Charlottesville, Virginia. Grounded in mitochondrial biology, it develops oral small-molecule controlled metabolic accelerators for obesity and associated cardio-metabolic disease. Lead candidate HU6 is in Phase 2 development for metabolic dysfunction-associated steatohepatitis (MASH) and has reported Phase 2a data in obesity-related heart failure with preserved ejection fraction (HFpEF); RV-8451, an oral non-peptide GLP-1 receptor agonist for obesity, is in IND-enabling studies. Rivus is a therapeutics developer, not a software or technology vendor: it publishes no developer program, public API, SDK or machine-readable specification of any kind.
Rivus Pharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Clinical Trials.
Rivus Pharmaceuticals’ developer surface includes product news and 10 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 2
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Commercial 2
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 1
Properties that don't map to a standard resource type